Skip to content
OpenCapital
Get started

AnaptysBio, Inc. ANAB Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue$76.3MBeat by $54.4MDiluted EPS$0.52Beat by $1.58
Revenue estimate$21.9M
EPS estimate-$1.06

Next report

Aug 5, 2026 (In 3 weeks)
Revenue estimate$20.2M
EPS estimate-$0.13

Financials

Q3 2025

Income statement

See full
Revenue$76.3M+154%
Operating income$34.7M+252%
Net income$15.1M+146%
EPS (diluted)$0.52+146%

Balance sheet

See full
Cash & equivalents$109.8M-42.7%
Total debt$14.6M-11.4%
Total equity-$29.4M-135%
Total assets$353.1M-28.4%

Cash flow

See full
Operating cash flow-$27.4M-171%
CapEx$12.0K-65.7%
Free cash flow-$27.4M-170%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$856.53M-15.3%
Enterprise value$761.31M-9.0%
P/S5.1×-12.6×

Profitability

See full
Operating margin-16.9%-8.2pp
Net margin-49.9%-22.6pp
FCF margin-85.8%-29.6pp

Returns & leverage

See full
Current ratio8.7×-1.5×

Versus estimates

Revenue

Q1 2026$25.6MBeat by $6.7MQ4 2025$108.2MBeat by $21.2M
Q3 2025$76.3MBeat by $54.4M
Q2 2025$22.3MBeat by $10.6MQ1 2025$27.8MBeat by $12.5MQ4 2024$43.1MBeat by $35.3M

Diluted EPS

Q1 2026-$1.84Miss by $1.52Q4 2025$1.58Beat by $0.69
Q3 2025$0.52Beat by $1.58
Q2 2025-$1.34Beat by $0.16Q1 2025-$1.28Beat by $0.02Q4 2024-$0.72Beat by $0.83

Ask the moment AnaptysBio, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did AnaptysBio, Inc. report Q3 2025 earnings?
AnaptysBio, Inc. (ANAB) reported Q3 2025 earnings on November 4, 2025 before market open.
What were AnaptysBio, Inc.'s Q3 2025 revenue and EPS?
AnaptysBio, Inc. reported revenue of $76.3M and diluted EPS of $0.52 for Q3 2025.
Did AnaptysBio, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $21.9M by $54.4M. EPS beat the consensus estimate of $-1.06 by $1.58.
How did AnaptysBio, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 154.3% from $30.0M a year earlier.
Where can I find AnaptysBio, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001370053-25-000088) and the 10-Q periodic report (0001370053-25-000089) directly on SEC EDGAR. The filing index links above go to sec.gov.